Nuvation Bio (NUVB) Q2 2026 earnings summary

Executive summary

• IBTROZI achieved 25% quarter-over-quarter net revenue growth to $23.2 million, becoming the market leader in ROS1 TKI new patient starts, with 85% of new patients in the first-line setting and broad adoption across academic, community, and integrated delivery networks.

• Commercial launch of IBTROZI began in June 2025 in the U.S. after FDA approval, with additional approvals in Japan and China and significant partnerships, including a $58.7 million upfront payment from Eisai for European commercialization.

• Safusidenib's clinical program expanded with new studies for all IDH1 mutant glioma segments, including post-vorasidenib patients, and positive long-term Phase 2 data were announced.

• The company completed a 5x oversubscribed convertible debt financing, raising $279.1 million net, and an additional $36.5 million from an overallotment, strengthening its balance sheet and retiring higher-cost debt.

• Expanded global rights for safusidenib and taletrectinib through amended licenses with Daiichi Sankyo.

Financial highlights

• Q2 2026 total revenue was $31.7 million, including $23.2 million from IBTROZI and $8.5 million from collaboration/license agreements, with six-month revenue at $114.9 million.

• Net loss for Q2 2026 was $62.8 million, or $(0.18) per share, compared to $59.0 million, or $(0.17) per share, in Q2 2025; six-month net loss was $57.4 million, improved from $112.2 million year-over-year.

• Operating expenses for Q2 were $73.3 million, with R&D at $30.7 million and SG&A at $42.6 million.

• Cash, cash equivalents, and marketable securities totaled $661.0 million as of June 30, 2026.

• Collaboration and license revenue rose sharply due to the Eisai upfront payment and increased royalties and product supply sales.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as R&D and commercialization investments continue, but current liquidity is expected to fund operations for at least the next 12 months.

• Expectation of continued stable gross-to-net deductions (~30%) and no significant changes to spending patterns for the remainder of 2026.

• Data from phase III safusidenib studies expected in 2029; update on DDC platform planned by year-end 2026.

• FDA accepted a supplemental NDA for IBTROZI with a target action date of January 4, 2027.